Holen Sie sich die Stockscreener-App
37.88
1.34%
0.50
Handel nachbörslich:
37.88
Schlusskurs vom Vortag:
$37.38
Offen:
$37.51
24-Stunden-Volumen:
2.52M
Relative Volume:
0.79
Marktkapitalisierung:
$10.20B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
21.40
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
+1.23%
1M Leistung:
+1.12%
6M Leistung:
-1.99%
1J Leistung:
+48.14%
1-Tages-Spanne:
$37.22
$37.93
1-Wochen-Bereich:
$36.23
$37.93
52-Wochen-Spanne:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.88 | 10.06B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Analyzing Exelixis Inc. with risk reward ratio chartsRisk Management & Precise Buy Zone Tips - Newser
Will Exelixis Inc. be affected by tariffs2025 Stock Rankings & Real-Time Market Sentiment Reports - خودرو بانک
Can Exelixis Inc. lead its sector in growth2025 Institutional Moves & AI Optimized Trading Strategy Guides - خودرو بانک
What drives Exelixis Inc.’s stock priceSwing Trade & Growth Focused Stock Pick Reports - خودرو بانک
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - Yahoo Finance
Is Exelixis Inc. building a consolidation baseEarnings Growth Report & Real-Time Volume Analysis - Newser
Exelixis, Inc. (EXEL): A Bull Case Theory - MSN
Can Exelixis Inc. be recession proofDividend Hike & Daily Growth Stock Investment Tips - خودرو بانک
Exelixis, Inc. (EXEL): A High-Conviction Biotech Play with Cash-Generative Momentum and a De-Risked Pipeline - AInvest
Using data models to predict Exelixis Inc. stock movementEarnings Miss & Weekly Watchlist of Top Performers - Newser
Ranking Exelixis Inc. among high performing stocks via tools2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Is Exelixis Inc.’s growth already priced inJuly 2025 Snapshot & Weekly Top Gainers Trade List - خودرو بانک
What candlestick patterns are forming on Exelixis Inc.Market Growth Report & Risk Managed Investment Entry Signals - Newser
Price momentum metrics for Exelixis Inc. explained2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Live market analysis of Exelixis Inc.2025 Analyst Calls & Growth Focused Entry Reports - Newser
Will Exelixis Inc. benefit from AI trendsRecession Risk & Precise Trade Entry Recommendations - خودرو بانک
Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves - Endpoints News
Institutional scanner results for Exelixis Inc.Weekly Stock Analysis & Short-Term Trading Alerts - Newser
Will Breakout in Exelixis Inc. Sustain Through Next WeekMarket Performance Report & Low Risk Entry Point Guides - 더경남뉴스
Is Exelixis Inc. backed by strong institutional buyingJuly 2025 Review & Safe Capital Growth Tips - خودرو بانک
Statistical indicators supporting Exelixis Inc.’s strengthWeekly Profit Summary & Daily Risk Controlled Trade Plans - Newser
What’s Exelixis Inc.’s historical returnJuly 2025 Short Interest & Stepwise Trade Execution Plans - خودرو بانک
Intraday pattern recognizer results for Exelixis Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - Newser
Exelixis Cuts 130 Jobs as Company Shuts Down Pennsylvania Facility - AInvest
Exelixis Investigated for Misleading Statements, Shares Fall 16.8% - AInvest
Exelixis shuttering Pennsylvania site, laying off 130 employees - Seeking Alpha
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Exelixis’ Strategic Momentum in Oncology Innovation - AInvest
Exelixis at Citi’s Biopharma Conference: Strategic Growth and Innovation - Investing.com
Is Exelixis Inc. stock bottoming outPortfolio Update Summary & Low Risk High Reward Trade Ideas - Newser
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 03 - MarketScreener
Exelixis (EXEL): Leveraging ZANZA's Breakthrough and Strong Cash Flow for Long-Term Value Creation - AInvest
Exelixis Presents at 2025 Wells Fargo Healthcare Conference: Key Takeaways and Insights - AInvest
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Transcript : Exelixis, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 12 - MarketScreener
Building trade automation scripts for Exelixis Inc.Rate Cut & Daily Profit Maximizing Trade Tips - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - cnhinews.com
Breakout Watch: Is Exelixis Inc. a play on infrastructure spendingM&A Rumor & Smart Allocation Stock Reports - خودرو بانک
Take Profit: Can Exelixis Inc. lead its sector in growthPortfolio Return Report & AI Powered Buy and Sell Recommendations - خودرو بانک
What is the earnings history of Exelixis Inc.Quarterly Trade Summary & Daily Stock Trend Reports - خودرو بانک
Sector ETF performance correlation with Exelixis Inc.2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Exelixis Inc. stock retracement – recovery analysisInflation Watch & Free Risk Controlled Daily Trade Plans - Newser
Using Bollinger Bands to evaluate Exelixis Inc.July 2025 Update & Consistent Profit Alerts - Newser
How to interpret RSI for Exelixis Inc. stockJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - Newser
Can Exelixis Inc. recover in the next quarterDollar Strength & Growth Focused Investment Plans - Newser
Exelixis gains after win in patent fight with MSN over Cabometyx - MSN
Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial - MSN
Is Exelixis Inc. stock forming a cup and handleJuly 2025 Trade Ideas & Consistent Growth Equity Picks - خودرو بانک
How to contact the Daily Bulletin - FinancialContent
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):